Pain CROs

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Italian CRO providing Phase I clinical pharmacology studies including bioequivalence, food-effect, and drug interaction trials from its dedicated Phase I unit in Milan.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Europe's first specialist CRO dedicated to psychedelic compound clinical research, providing full-service trial design and execution for novel psychiatric treatments in the UK.

Clinical technology company providing eCOA, eConsent, and clinical data capture solutions integrated with CRO-like trial management capabilities for decentralized and hybrid clinical trials.

The only global full-service CRO focused exclusively on CNS drug development, with involvement in 22 FDA-approved CNS therapies across 13 indications.

New York-based Phase I CRO operating an 80-bed clinical pharmacology unit for first-in-human, CNS, cardiac safety, and abuse liability studies.

Specialty CRO focused exclusively on CNS clinical trials, neurocognitive endpoint assessments, and central rater training for Phase I-III neuropsychiatric studies.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Dutch CDMO specialising in controlled substance manufacturing and schedule I-V API synthesis for clinical trial and commercial supply under DEA and EMA licences.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

Integrated drug discovery and development services company providing medicinal chemistry, ADME/DMPK, pharmacology, and clinical research from India, US, and China operations.

Phase I-III CRO and integrated research site network specialising in CNS, pain, obesity, and metabolic disease with wholly-owned clinical units in California.

Specialist topical and transdermal formulation development CRO and CDMO offering dermal PK, in vitro permeation, bioequivalence, and formulation development services.

Specialized CDMO focused exclusively on sustained-release long-acting injectable formulation development, aseptic fill-finish, and lyophilization.

Canadian full-service CRO providing clinical research services from Phase I through Phase IV with particular expertise in bioequivalence studies and pharmacokinetic trials.

Taipei-based drug development company and CRO specializing in oncology, running Phase I-III clinical trials for new cancer therapies and out-licensing proprietary pipeline assets.

Clinical research site in Phoenix conducting Phase I-IV clinical trials with particular strength in CNS, pain, and metabolic disease studies with rapid enrollment capabilities.

Multi-site clinical research organization conducting Phase I-IV trials with a network of dedicated research sites across the upper Midwest specializing in diverse therapeutic areas.

Translational pharmaceutics CRO/CDMO uniquely combining formulation development and clinical pharmacology under one roof, accelerating drug development timelines by running formulation and clinical testing simultaneously.

London-based Phase 1 clinical research unit specializing in early phase clinical trials, pharmacokinetics, and healthy volunteer studies. Located at Guy's Hospital campus.

Ireland-based specialty pharmaceutical development group providing formulation, analytical, and clinical supply services for oral, topical, and injectable dosage forms.

US-based early phase CRO specializing in cardiac safety (thorough QT/QTc) studies, abuse deterrent formulation, and human abuse liability studies. Operates a 120-bed clinical facility.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

UK-based CDMO specialising in inhaled drug product development including dry powder inhalers, metered dose inhalers, and nasal spray formulations.

Indian CRO providing Phase I clinical pharmacology, bioanalytical services, and bioequivalence studies from a 230-bed clinical pharmacology unit in Ahmedabad with USFDA and EMA track record.